File Description: 


This document provides guidance for referring Duke clinicians for Emergency Use Authorized Monoclonal Antibody Infusion (MAB) for Mild/Moderate COVID-19. COVID-19 MABs are investigational drugs with Emergency Use Authorization (EUA) from the FDA. MAB infusions are associated with reduced rates of hospitalization, especially among patients at HIGH RISK of disease progression. If administered, the medication is free o Patients may be charged for the actual infusion and monitoring. If the patient is enrolled in a CLINICAL TRIAL, the infusion and monitoring will be covered by the trial. Uploaded 5.28.21

The information on this site is intended solely for the internal use by Duke University Health System, its medical staff, clinicians and staff and any and all content or services available on or through this website is prohibited to be shared with external parties with the exception of those marked as patient communications that would be disclosed to patients.